Taysha Gene Therapies 관리

관리 기준 확인 3/4

Taysha Gene Therapies CEO는 Sean Nolan, Dec2022 에 임명되었습니다 의 임기는 1.92 년입니다. 총 연간 보상은 $ 1.52M, 39.4% 로 구성됩니다. 39.4% 급여 및 60.6% 보너스(회사 주식 및 옵션 포함). 는 $ 3.38K 가치에 해당하는 회사 주식의 0.001% 직접 소유합니다. 3.38K. 경영진과 이사회의 평균 재임 기간은 각각 1.9 년과 3.8 년입니다.

주요 정보

Sean Nolan

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	39.4%
CEO 임기	1.9yrs
CEO 소유권	0.0006%
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

CEO 보상 분석

Sean Nolan 의 보수는 Taysha Gene Therapies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$23m
Jun 30 2024	n/a	n/a	-US$114m
Mar 31 2024	n/a	n/a	-US$118m
Dec 31 2023	US$2m	US$600k	-US$112m
Sep 30 2023	n/a	n/a	-US$214m
Jun 30 2023	n/a	n/a	-US$124m
Mar 31 2023	n/a	n/a	-US$133m
Dec 31 2022	US$2m	US$25k	-US$166m
Sep 30 2022	n/a	n/a	-US$161m
Jun 30 2022	n/a	n/a	-US$186m
Mar 31 2022	n/a	n/a	-US$193m
Dec 31 2021	US$321k	n/a	-US$175m
Sep 30 2021	n/a	n/a	-US$142m
Jun 30 2021	n/a	n/a	-US$106m
Mar 31 2021	n/a	n/a	-US$87m
Dec 31 2020	US$457k	n/a	-US$60m

보상 대 시장: Sean 의 총 보상 ($USD 1.52M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.16M ).

보상과 수익: Sean 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sean Nolan (56 yo)

1.9yrs

테뉴어

US$1,522,515

보상

Mr. Sean P. Nolan serves as Executive Chairman of Jaguar Gene Therapy, LLC. Mr. Nolan has been Chairman of the board at Taysha Gene Therapies, Inc since March 2020 and serves as its Chief Executive Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sean Nolan	CEO & Chairman	1.9yrs	US$1.52m	0.00057% $ 3.4k
Sukumar Nagendran	President	1.9yrs	US$1.25m	0.017% $ 98.9k
Kamran Alam	CFO & Corporate Secretary	4.3yrs	US$975.40k	0.077% $ 457.5k
Hayleigh Collins	Director of Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Tracy Porter	Chief People Officer	3.8yrs	데이터 없음	데이터 없음
Frederick Porter	Chief of Staff & Technical Operations Officer	1.8yrs	데이터 없음	데이터 없음
Emily McGinnis	Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead	no data	데이터 없음	데이터 없음
Sean McAuliffe	Chief Business Officer	no data	데이터 없음	데이터 없음
Steven Gray	Chief Scientific Advisor of UT Southwestern Gene Therapy Program	no data	데이터 없음	데이터 없음
Berge Minassian	Chief Medical Advisor of UT Southwestern Gene Therapy Program	no data	데이터 없음	데이터 없음
Rumana Haque-Ahmed	Chief Regulatory Officer	no data	데이터 없음	데이터 없음
Meredith Schultz	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: TSHA 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sean Nolan	CEO & Chairman	4.7yrs	US$1.52m	0.00057% $ 3.4k
Sukumar Nagendran	President	4.3yrs	US$1.25m	0.017% $ 98.9k
Phillip Donenberg	Independent Director	4.3yrs	US$73.82k	0.056% $ 329.8k
Sean Stalfort	Independent Director	1.4yrs	US$35.09k	0.94% $ 5.6m
Paul Manning	Board Observer	1.4yrs	US$22.81k	12.12% $ 71.8m
Wendy Chung	Independent Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Deborah Bilder	Independent Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
David Dimmock	Independent Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Laura Sepp-Lorenzino	Independent Director	4yrs	US$76.90k	0% $ 0
Alison Long	Independent Director	less than a year	US$77.96k	0% $ 0
Gerald Lipshutz	Independent Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Benedikt Schoser	Member of Independent Scientific Advisory Board	3.1yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: TSHA 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Taysha Gene Therapies 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Board Observer recently bought US$163k worth of stock

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

CFO & Corporate Secretary notifies of intention to sell stock

Insider recently sold US$61k worth of stock

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Taysha Gene Therapies, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taysha Gene Therapies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $74.981029 million.

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Taysha Gene Therapies, Inc. Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Taysha Gene Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Board Observer recently bought US$163k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

CFO & Corporate Secretary notifies of intention to sell stock

Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Consensus estimates of losses per share improve by 33%

Taysha Gene Therapies, Inc. announced that it expects to receive $149.952767 million in funding from a group of investors

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Taysha Gene Therapies, Inc. Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Insider recently sold US$61k worth of stock

New minor risk - Insider selling

Insider recently sold US$308k worth of stock

Taysha Gene Therapies, Inc. Announces First Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc., Annual General Meeting, Jun 22, 2023

Taysha Gene Therapies, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 20% to US$5.77

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy

Price target decreased by 11% to US$14.57

Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer

Price target decreased to US$15.36

Price target decreased to US$16.79

High number of new and inexperienced directors

Price target decreased to US$17.21

Taysha Gene Therapies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Price target decreased to US$22.46

Taysha Gene Therapies, Inc. announced that it expects to receive $50 million in funding from Astellas Pharma Inc.

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 2000 Growth Index

Chief Technical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome